Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 14/20 | 0.40 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222845 | 0.94 | KDM4E (0.39) | FAAHUBE2MDCUN1D1KDM4E | |
| SCHEMBL2221367 | 0.90 | THRB (0.41) | FAAHUBE2MDCUN1D1ALDH1A1KDM4E | |
| SCHEMBL2223116 | 0.89 | MAPT (0.49) | FAAHUBE2MDCUN1D1ALDH1A1KDM4E | |
| SCHEMBL2223593 | 0.88 | SLC6A9 (0.36) | FAAHUBE2MDCUN1D1KDM4EPOLB | |
| SCHEMBL2226396 | 0.85 | CCR5 (0.40) | UBE2MDCUN1D1ALDH1A1KDM4EMAPT | |
| SCHEMBL14485091 | 0.85 | KDM4E (0.42) | FAAHALDH1A1KDM4E | |
| SCHEMBL2223469 | 0.84 | SLC6A4 (0.40) | KDM4EPOLBMAPTNPSR1L3MBTL1 | |
| SCHEMBL2223104 | 0.83 | CCR5 (0.39) | UBE2MDCUN1D1ALDH1A1KDM4E | |
| SCHEMBL2221583 | 0.83 | HTR2A (0.38) | FAAH | |
| SCHEMBL2222776 | 0.83 | L3MBTL1 (0.39) | UBE2MDCUN1D1ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | claimed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | claimed |
| EP-2729149-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | FAAH 1643/4885UBE2M 2212/4885DCUN1D1 3698/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | FAAH 1207/4885UBE2M 2641/4885DCUN1D1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.